JP6977945B2 - A composition for promoting GLP-1 secretion and a method for producing the composition. - Google Patents
A composition for promoting GLP-1 secretion and a method for producing the composition. Download PDFInfo
- Publication number
- JP6977945B2 JP6977945B2 JP2016095639A JP2016095639A JP6977945B2 JP 6977945 B2 JP6977945 B2 JP 6977945B2 JP 2016095639 A JP2016095639 A JP 2016095639A JP 2016095639 A JP2016095639 A JP 2016095639A JP 6977945 B2 JP6977945 B2 JP 6977945B2
- Authority
- JP
- Japan
- Prior art keywords
- rice
- globulin
- glp
- composition
- secretion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Description
本発明はインクレチンの1種であるグルカゴン様ペプチド−1(GLP−1)の腸からの分泌を促進させるために用いられるGLP−1分泌促進用組成物、及び該組成物の製造方法に関する。 The present invention relates to a GLP-1 secretagogue composition used for promoting glucagon-like peptide-1 (GLP-1), which is a kind of incretin, from the intestine, and a method for producing the composition.
GLP−1は腸の上皮に存在するL−細胞から内分泌されるホルモンであり、糖分の摂取に伴うインスリン分泌を促進して食後の血糖値の上昇を抑制する作用を有する。またGLP−1はインスリン分泌を司る膵臓β細胞の増殖を促進する作用やこれを保護する作用を有し、また肝臓、脂肪細胞、心血管系、神経系への様々な作用が報告されている。分泌されたGLP−1は上記の活性を有するものの、血中や組織中に存在するジペプチジルペプチダーゼIV(DPP−IV)の作用により短時間の内に不活性型に変換されることが知られている。それゆえDPP−IVの作用を受けないGLP−1受容体アゴニストの探索やDPP−IVを阻害してGLP−1の作用を持続させる検討が2型糖尿病に対する医薬品の分野において注目されている。食品分野においては摂取に伴ってGLP−1の分泌を高める食事成分の検討が進められている。
GLP−1の分泌を促進する成分としてアミノ酸であるグルタミンや乳清タンパク質が知られている。
また本発明者らの検討によりトウモロコシタンパク質であるゼインの加水分解物や米胚乳タンパク質並びに米糠タンパク質の加水分解物がGLP−1の分泌を強力に促進することが判明している(例えば、特許文献1及び非特許文献1)。
GLP-1 is a hormone endocrine from L-cells present in the epithelium of the intestine, and has an action of promoting insulin secretion associated with sugar intake and suppressing an increase in postprandial blood glucose level. In addition, GLP-1 has an action of promoting the proliferation of pancreatic β cells that control insulin secretion and an action of protecting the proliferation, and various actions on the liver, adipocytes, cardiovascular system, and nervous system have been reported. .. Although the secreted GLP-1 has the above-mentioned activity, it is known that it is converted to the inactive form within a short time by the action of dipeptidyl peptidase IV (DPP-IV) present in blood and tissues. ing. Therefore, the search for a GLP-1 receptor agonist that is not affected by DPP-IV and the study of inhibiting DPP-IV to sustain the action of GLP-1 are attracting attention in the field of pharmaceuticals for type 2 diabetes. In the food field, studies on dietary components that increase the secretion of GLP-1 with ingestion are underway.
Glutamine, which is an amino acid, and whey protein are known as components that promote the secretion of GLP-1.
Further, it has been found by the studies of the present inventors that a hydrolyzate of zein, which is a corn protein, a hydrolyzate of rice endosperm protein, and a hydrolyzate of rice bran protein strongly promote the secretion of GLP-1 (for example, Patent Document). 1 and Non-Patent Document 1).
しかし、食事成分によるGLP−1分泌促進機能が発揮されるには多量の該食事成分を摂取することが要求される。また、そのために糖質や脂質を多量に摂取することも糖・脂質代謝改善を目的とする上ではふさわしくない。このため、GLP−1分泌促進活性が高い成分が求められている。 However, in order for the GLP-1 secretion promoting function of the dietary component to be exhibited, it is required to ingest a large amount of the dietary component. In addition, for that reason, ingesting a large amount of sugar and lipid is not suitable for the purpose of improving sugar and lipid metabolism. Therefore, a component having high GLP-1 secretion promoting activity is required.
本発明は、上記事情に鑑みてなされたものであり、GLP−1分泌促進活性に優れるGLP−1分泌促進用組成物、及び該組成物の製造方法を提供することを目的とする。 The present invention has been made in view of the above circumstances, and an object of the present invention is to provide a GLP-1 secretion-promoting composition having excellent GLP-1 secretion-promoting activity, and a method for producing the composition.
本発明者らは鋭意検討を重ねた結果、米胚乳タンパク質の中で食塩水に溶解可能なタンパク質画分であるグロブリンに強いGLP−1分泌促進活性が存在すること、米胚乳グロブリンのペプシン消化物を投与した動物の門脈血におけるGLP−1濃度が、米胚乳グロブリンのペプシン消化物を投与しない動物やグロブリン以外のタンパク質のペプシン消化物を投与した動物の門脈血と比較して有意に高いこと、さらにグロブリンのペプシン消化物を投与した動物の糖負荷試験において糖を腹腔内投与した動物の血糖値上昇が有意に抑制されることを見出し、本発明を完成させるに至った。 As a result of diligent studies, the present inventors have found that globulin, which is a protein fraction soluble in saline, has a strong GLP-1 secretion-promoting activity among rice germ milk proteins, and that the pepsin digested product of rice germ milk globulin is present. GLP-1 concentration in the portal blood of animals treated with globulin is significantly higher than that of animals not treated with the pepsin digested product of rice germ milk globulin and animals treated with the pepsin digested product of non-globulin protein. Furthermore, in a sugar loading test of an animal to which a globulin pepsin digested product was administered, it was found that the increase in blood glucose level of an animal to which sugar was intraperitoneally administered was significantly suppressed, and the present invention was completed.
具体的には、本発明は以下の通りである。
本発明の第1の態様は、米胚乳グロブリンを有効成分として含むGLP−1分泌促進用組成物である。
本発明の第2の態様は、米胚乳タンパク質量に対する米胚乳グロブリンの含有量が15質量%以上であるGLP−1分泌促進用組成物である。
本発明の第3の態様は、通常の国産米と比較して米胚乳グロブリンの含有量が1.5倍以上である米品種のアルカリ抽出米胚乳タンパク質を含有するGLP−1分泌促進用組成物である。
本発明の第4の態様は、米胚乳タンパク質に米胚乳グロブリンを添加する工程を含むGLP−1分泌促進用組成物の製造方法である。
本発明の第5の態様は、通常の国産米と比較して米胚乳グロブリンの含有量が1.5倍以上である米品種からアルカリ抽出米胚乳タンパク質を得る工程を含むGLP−1分泌促進用組成物の製造方法である。
Specifically, the present invention is as follows.
The first aspect of the present invention is a composition for promoting GLP-1 secretion containing rice endosperm globulin as an active ingredient.
A second aspect of the present invention is a composition for promoting GLP-1 secretion in which the content of rice endosperm globulin with respect to the amount of rice endosperm protein is 15% by mass or more.
A third aspect of the present invention is a composition for promoting GLP-1 secretion containing an alkali-extracted rice endosperm protein of a rice variety having a rice endosperm globulin content of 1.5 times or more as compared with ordinary domestic rice. Is.
A fourth aspect of the present invention is a method for producing a composition for promoting GLP-1 secretion, which comprises a step of adding rice endosperm globulin to rice endosperm protein.
A fifth aspect of the present invention is for promoting GLP-1 secretion, which comprises a step of obtaining an alkali-extracted rice endosperm protein from a rice variety having a rice endosperm globulin content of 1.5 times or more as compared with ordinary domestic rice. It is a method for producing a composition.
本発明のGLP−1分泌促進用組成物はGLP−1分泌促進活性に優れる。
本発明によれば、米胚乳グロブリンを摂取することによりGLP−1分泌量が増加し、その結果として食後血糖値の上昇を抑制できることからGLP−1分泌低下に起因する糖尿病の予防や治療に貢献する食品又は医薬品を提供することができる。
The GLP-1 secretagogue composition of the present invention is excellent in GLP-1 secretagogue activity.
According to the present invention, ingestion of rice germ milk globulin increases the amount of GLP-1 secretion, and as a result, the increase in postprandial blood glucose level can be suppressed, which contributes to the prevention and treatment of diabetes caused by the decrease in GLP-1 secretion. Can provide foods or medicines to be used.
以下、本発明の実施形態について説明するが、本発明は以下の実施形態に限定されるものではない。 Hereinafter, embodiments of the present invention will be described, but the present invention is not limited to the following embodiments.
<GLP−1分泌促進用組成物、及び該組成物の製造方法>
本発明の第1の態様に係るGLP−1分泌促進用組成物は、米胚乳グロブリンを有効成分として含む。
本発明の第2の態様に係るGLP−1分泌促進用組成物は、米胚乳タンパク質量に対する米胚乳グロブリンの含有量が15質量%以上である。
本発明の第3の態様に係るGLP−1分泌促進用組成物は、通常の国産米と比較して米胚乳グロブリンの含有量が1.5倍以上である米品種のアルカリ抽出米胚乳タンパク質を含有する。
本発明の第4の態様に係るGLP−1分泌促進用組成物の製造方法は、米胚乳タンパク質に米胚乳グロブリンを添加する工程を含む。
本発明の第5の態様に係るGLP−1分泌促進用組成物の製造方法は、通常の国産米と比較して米胚乳グロブリンの含有量が1.5倍以上である米品種からアルカリ抽出米胚乳タンパク質を得る工程を含む。
<Composition for promoting GLP-1 secretion and method for producing the composition>
The GLP-1 secretion-promoting composition according to the first aspect of the present invention contains rice endosperm globulin as an active ingredient.
The composition for promoting GLP-1 secretion according to the second aspect of the present invention has a content of rice endosperm globulin in an amount of 15% by mass or more based on the amount of rice endosperm protein.
The GLP-1 secretion-promoting composition according to the third aspect of the present invention comprises an alkali-extracted rice endosperm protein of a rice variety having a rice endosperm globulin content of 1.5 times or more as compared with ordinary domestic rice. contains.
The method for producing a GLP-1 secretagogue composition according to a fourth aspect of the present invention includes a step of adding rice endosperm globulin to rice endosperm protein.
The method for producing a GLP-1 secretagogue composition according to a fifth aspect of the present invention is an alkali-extracted rice from a rice variety having a rice endosperm globulin content of 1.5 times or more as compared with ordinary domestic rice. Includes the step of obtaining endosperm protein.
(米胚乳タンパク質)
本発明において「米胚乳タンパク質」とは米胚乳より抽出された米タンパク質を指す。
米胚乳タンパク質は精白米又は米粉をアルカリで処理して抽出されるタンパク質溶液を中和して沈殿物を回収することにより、又は精白米又は米粉にアミラーゼを作用させて澱粉質を加水分解した後に残存する成分を回収する方法により調製することができる。
(米胚乳グロブリン)
本発明において「米胚乳グロブリン」とは精白米、米粉又は米胚乳タンパク質から食塩水により抽出されるグロブリンを指す。
本発明において「米胚乳グロブリン」は、米胚乳グロブリンが消化酵素(例えば、ペプシン)等のタンパク質分解酵素によって部分的に分解された消化物であってもよい。
米胚乳グロブリンの主成分は分子量26,000ダルトンのα−グロブリンである。米胚乳グロブリンは米胚乳又はその粉砕物を0.5〜5Mの食塩水に浸漬することにより抽出されるが、この条件では純水で抽出されるアルブミンも同時に抽出されることから、原料を予め水で抽出してアルブミンを除去した原料を用いて、0.5〜5Mの食塩水に浸漬することにより抽出することが好ましい。
(Rice endosperm protein)
In the present invention, "rice endosperm protein" refers to rice protein extracted from rice endosperm.
Rice germ milk protein is obtained by treating polished rice or rice flour with an alkali to neutralize the protein solution extracted to recover the precipitate, or by allowing the polished rice or rice flour to act on amylases to hydrolyze the starch. It can be prepared by a method of recovering the remaining components.
(Rice endosperm globulin)
In the present invention, "rice endosperm globulin" refers to globulin extracted from polished rice, rice flour or rice endosperm protein with saline.
In the present invention, the "rice germ globulin" may be a digested product in which rice germ globulin is partially decomposed by a proteolytic enzyme such as a digestive enzyme (for example, pepsin).
The main component of rice endosperm globulin is α-globulin with a molecular weight of 26,000 daltons. Rice germ globulin is extracted by immersing rice germ milk or its pulverized product in 0.5 to 5 M saline solution. Under this condition, albumin extracted with pure water is also extracted at the same time, so the raw material is previously used. It is preferable to extract by immersing in a 0.5 to 5 M saline solution using a raw material extracted with water and from which albumin has been removed.
精白米又は米粉を水で抽出して遠心分離や濾過等で抽出液を除去した後の残渣に0.5〜5Mの食塩水を加えて抽出し、遠心分離又は濾過により抽出液を回収する。米胚乳タンパク質を原料とする場合でも同様に水抽出後に食塩水抽出を行うことが好ましい。
抽出されたグロブリンを抽出液より回収する方法としては、透析膜を用いて透析後に乾燥させる方法、限外濾過膜を用いて脱塩及び濃縮後に乾燥させる方法等が挙げられるが、食塩水中のグロブリンは酸性条件下での溶解性が低いことからグロブリン抽出液に酸を加えてグロブリンを沈殿させ、これを遠心分離や濾過により回収することによっても米胚乳グロブリンの精製品の回収が可能である。
本発明における米胚乳グロブリンの少なくとも一部は、上述のようにして得られた米胚乳グロブリンの精製品であることが好ましい。
Polished rice or rice flour is extracted with water, and the extract is removed by centrifugation or filtration. Then, 0.5 to 5 M saline solution is added to the residue to extract, and the extract is recovered by centrifugation or filtration. Even when rice endosperm protein is used as a raw material, it is preferable to perform saline extraction after water extraction in the same manner.
Examples of the method for recovering the extracted globulin from the extract include a method of drying after dialysis using a dialysis membrane, a method of desalting and concentrating using an ultrafiltration membrane, and the like, and globulin in saline solution. Since globulin has low solubility under acidic conditions, it is possible to recover the refined product of rice germ milk globulin by adding an acid to the globulin extract to precipitate globulin and then recovering it by centrifugation or filtration.
It is preferable that at least a part of the rice endosperm globulin in the present invention is a refined product of the rice endosperm globulin obtained as described above.
米胚乳タンパク質量に対する米胚乳グロブリンの含有量は通常10質量%前後であるが、米胚乳タンパク質のより少ない摂取量でGLP−1の分泌を促進させるためには、本発明の組成物として米胚乳タンパク質量に対する米胚乳グロブリンの含有量が15質量%以上であることが好ましく、20質量%以上であることがより好ましく、50質量%以上であることがさらに好ましく、80質量%以上であることが特に好ましい。
米胚乳グロブリンの含有量の上限値としては特に制限はないが、98質量%以下であることが好ましい。
米胚乳タンパク質量に対する米胚乳グロブリンの上記含有量を達成する方法は特に制限はないが、米胚乳タンパク質に米胚乳グロブリンを添加することが挙げられる。
米胚乳タンパク質量に対する米胚乳グロブリンの含有量は、得られた米胚乳グロブリンの精製品をSDS−PAGEに供し、26kダルトンのα−グロブリンの含有量をデンシトメーターにより測定することにより算出することができる。
The content of rice germ globulin with respect to the amount of rice germ protein is usually around 10% by mass, but in order to promote the secretion of GLP-1 with a lower intake of rice germ protein, rice germ milk as the composition of the present invention. The content of rice embryo milk globulin with respect to the amount of protein is preferably 15% by mass or more, more preferably 20% by mass or more, further preferably 50% by mass or more, and preferably 80% by mass or more. Especially preferable.
The upper limit of the content of rice endosperm globulin is not particularly limited, but is preferably 98% by mass or less.
The method for achieving the above-mentioned content of rice endosperm globulin with respect to the amount of rice endosperm protein is not particularly limited, and examples thereof include adding rice endosperm globulin to rice endosperm protein.
The content of rice germ globulin relative to the amount of rice endosperm protein shall be calculated by subjecting the obtained refined rice germ globulin to SDS-PAGE and measuring the content of α-globulin of 26 k Dalton with a densitometer. Can be done.
米の品種の中には春陽やLGC1、LGCソフト等の低グルテリン米が知られている。これら低グルテリン米の多くは米胚乳グロブリンの含有量が通常の国産米(コシヒカリ、ササニシキ等)と比較して1.5倍以上(例えば、約1.5〜2倍)である。このような品種の米から抽出した米胚乳タンパク質であれば通常の米胚乳タンパク質の摂取と比較してより少ない摂取量でGLP−1の分泌を促進させることができることから、食塩水を用いて米胚乳グロブリンの分別抽出を行わなくとも通常の米胚乳タンパク質を抽出する方法で回収される組成物をそのまま用いることもできる。 Among the rice varieties, low glutelin rice such as Chunyang, LGC1, and LGC soft is known. Most of these low glutelin rices have a rice endosperm globulin content of 1.5 times or more (for example, about 1.5 to 2 times) as compared with ordinary domestic rice (Koshihikari, Sasanishiki, etc.). Since rice endosperm protein extracted from such varieties of rice can promote GLP-1 secretion with a smaller intake than normal rice endosperm protein intake, rice using saline solution is used. The composition recovered by the usual method for extracting rice endosperm protein can also be used as it is without performing the fractional extraction of the endosperm globulin.
米胚乳グロブリンをそのまま、又はタンパク質分解酵素(例えば、ペプシン等の消化酵素)を用いて分解して得られるペプチドを含有する組成物をGLP−1分泌促進用の食品又は医薬品として用いることができる。
本発明のGLP−1分泌促進用組成物の形態としては、米胚乳グロブリンを有効成分として含んでいる限り特に制限はなく、米菓組成物、粉(パウダー)、液体(例えば、飲料)、サプリメント等の食品、医薬品等が挙げられ、米そのものであってもよい。
例えば、本発明のGLP−1分泌促進用組成物の形態が米である場合、米を通常の主食として摂取することでGLP−1の分泌を促進できる。
ここで、米菓組成物とは、米粒又は米粉を原料として製造される米菓の少なくとも一部を組成する組成物である。米菓組成物としては、米又は米粉を原料とした例えば、せんべい類、ライスクラッカー類、あられ類、おかき類、かきもち、ライススナック、シリアルなどが挙げられる。
A composition containing a peptide obtained by degrading rice embryo milk globulin as it is or by using a proteolytic enzyme (for example, a digestive enzyme such as pepsin) can be used as a food or pharmaceutical for promoting GLP-1 secretion.
The form of the GLP-1 secretagogue composition of the present invention is not particularly limited as long as it contains rice germ milk globulin as an active ingredient, and is a rice cracker composition, powder (powder), liquid (for example, beverage), supplement. Foods such as, pharmaceuticals, etc. may be mentioned, and rice itself may be used.
For example, when the form of the composition for promoting GLP-1 secretion of the present invention is rice, the secretion of GLP-1 can be promoted by ingesting rice as a normal staple food.
Here, the rice cracker composition is a composition that composes at least a part of rice crackers produced from rice grains or rice flour as a raw material. Examples of the rice cracker composition include rice crackers, rice crackers, hail, okaki, kakimochi, rice snacks, and cereals made from rice or rice flour.
本発明のGLP−1分泌促進用組成物の形態が医薬品である場合、経口的に投与することができる。患者の年齢、症状により適宜投与方法を選択することができる。その投与量は、年齢、投与経路、投与回数により異なり、当業者であれば適宜選択できる。
経口投与した場合の投与量としては特に制限はないが、一般的には一回につき体重1kgあたり0.1μg〜10mg程度の範囲である。
When the form of the GLP-1 secretagogue composition of the present invention is a pharmaceutical product, it can be orally administered. The administration method can be appropriately selected according to the patient's age and symptoms. The dose varies depending on the age, route of administration, and frequency of administration, and can be appropriately selected by those skilled in the art.
The dose when orally administered is not particularly limited, but is generally in the range of about 0.1 μg to 10 mg per 1 kg of body weight at a time.
上記食品又は医薬品は、食後血糖値の上昇を抑制できることからGLP−1分泌低下に起因する糖尿病の予防や治療に貢献し得る。
特に、本発明の組成物は、GLP−1分泌に基づき、投与後、遅くとも30分以内(好ましくは15分以内)に即効性の血糖値上昇抑制効果を発揮する。したがって、食後直ぐに投与してもよいが、食後15分以上経過後(好ましくは30分以上経過後、更に好ましくは1時間以上経過後)の血糖値が十分に上昇してしまった後であっても即効性の血糖値上昇抑制効果が期待される。また、米由来であることからも、患者にストレスをかけないGLP−1分泌低下に起因する血糖値上昇を抑制する食品又は医薬品として期待される。
Since the above-mentioned foods or pharmaceuticals can suppress an increase in postprandial blood glucose level, they can contribute to the prevention and treatment of diabetes caused by a decrease in GLP-1 secretion.
In particular, the composition of the present invention exerts an immediate effect of suppressing an increase in blood glucose level within 30 minutes (preferably within 15 minutes) at the latest after administration based on GLP-1 secretion. Therefore, it may be administered immediately after a meal, but after a lapse of 15 minutes or more after a meal (preferably after a lapse of 30 minutes or more, more preferably after an lapse of 1 hour or more), the blood glucose level has sufficiently risen. However, it is expected to have an immediate effect of suppressing the rise in blood glucose level. In addition, since it is derived from rice, it is expected to be a food or pharmaceutical product that suppresses an increase in blood glucose level due to a decrease in GLP-1 secretion that does not stress the patient.
以下、実施例を示し、本発明を更に具体的に説明するが、本発明はこれらの実施例に限定されるものではない。 Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples.
[米胚乳タンパク質の調製]
国産精白米由来の米粉(製品名「パウダーライスDK」、新潟製粉株式会社製)50kgを、200Lの0.2%水酸化ナトリウム溶液に懸濁して20℃で一夜放置した。得られた懸濁液を、遠心分離機(製品名「H−130I」、株式会社コクサン製)に、流速約5L/分で給液し、回転数1,400rpmで遠心分離した。流出する遠心上清を集め、これを再度同一条件にて遠心分離を行うことにより澱粉粒が除去されたタンパク質抽出液を得た。この抽出液に6N塩酸を添加してpHを5.5に調整した。タンパク質の凝集体を上記の条件で遠心分離により回収し、100Lの水に懸濁した後に、同様の遠心分離操作をもう1度実施して湿タンパク質を得た。これを30Lの水に懸濁し、80℃で30分加熱殺菌後にホモジナイズを行い、噴霧乾燥することにより米タンパク質粉末(タンパク質純度90%)を得た。該米タンパク質粉末が米胚乳タンパク質に相当する。
[Preparation of rice endosperm protein]
50 kg of rice flour derived from domestically produced polished rice (product name "Powder Rice DK", manufactured by Niigata Seifun Co., Ltd.) was suspended in 200 L of 0.2% sodium hydroxide solution and left at 20 ° C. overnight. The obtained suspension was supplied to a centrifuge (product name "H-130I", manufactured by Kokusan Co., Ltd.) at a flow rate of about 5 L / min and centrifuged at a rotation speed of 1,400 rpm. The outflowing centrifugal supernatant was collected and centrifuged again under the same conditions to obtain a protein extract from which starch granules had been removed. 6N hydrochloric acid was added to this extract to adjust the pH to 5.5. The protein aggregates were recovered by centrifugation under the above conditions, suspended in 100 L of water, and then the same centrifugation operation was performed again to obtain wet protein. This was suspended in 30 L of water, sterilized by heating at 80 ° C. for 30 minutes, homogenized, and spray-dried to obtain rice protein powder (
[タンパク質の分画]
50kgのパウダーライスDKを、200Lの水道水に懸濁して20℃で一夜放置した。得られた懸濁液を、上記と同様の条件で遠心分離した。流出する遠心上清を集め、これを再度同一条件にて遠心分離を行うことにより上清を回収してアルブミン抽出液とした。この液を分画分子量50,000の限外濾過膜(旭化成社製AHP3010)で濃縮し、硫酸アンモニウムを50%飽和となるように添加した後に沈殿を回収した。沈殿を遠心分離により回収し、蒸留水に懸濁後に限外濾過膜(旭化成社製AHP1010)を用いて脱塩を行い、これを凍結乾燥してアルブミン画分とした。
[Protein fraction]
50 kg of powder rice DK was suspended in 200 L of tap water and left at 20 ° C. overnight. The obtained suspension was centrifuged under the same conditions as above. The outflowing centrifugal supernatant was collected and centrifuged again under the same conditions to collect the supernatant and use it as an albumin extract. This liquid was concentrated with an ultrafiltration membrane (AHP3010 manufactured by Asahi Kasei Corporation) having a molecular weight cut off of 50,000, ammonium sulfate was added so as to be 50% saturated, and then the precipitate was recovered. The precipitate was recovered by centrifugation, suspended in distilled water, desalted using an ultrafiltration membrane (AHP1010 manufactured by Asahi Kasei Corporation), and freeze-dried to obtain an albumin fraction.
アルブミン抽出液を分離した際に得られた沈殿に0.2%水酸化ナトリウム溶液に懸濁して20℃で一夜放置した。得られた懸濁液を、上記同様の遠心分離機で処理して上清を集め、これを再度同一条件にて遠心分離を行うことにより澱粉粒が除去されたタンパク質抽出液を得た。この液160Lに3.2kgの食塩を添加溶解し、さらに6N塩酸を加えてpH10.0に調整した。上記と同様の条件で遠心分離を行って沈殿(残渣画分)を回収するとともに、上清をさらに連続式ローターQNSを備えたコクサン社製冷却高速遠心分離機H−2000Bに流速約2L/分で供給し、回転数15,000rpmで連続遠心分離を行ってグルテリンの沈殿を除去した。遠心上清のpHを3.0に調整し、析出した沈殿を同様の連続遠心分離により回収した。沈殿を蒸留水5Lに懸濁して1時間室温で撹拌した後に再度遠心分離により沈殿を回収し、これを凍結乾燥してグロブリン画分を得た。
上記残渣画分は100Lの水に再度懸濁した後に同様の条件で遠心分離して沈殿を回収し、これを凍結乾燥することによりグルテリン+プロラミン画分とした。
The albumin extract was suspended in a 0.2% sodium hydroxide solution in the precipitate obtained when it was separated, and left at 20 ° C. overnight. The obtained suspension was treated with the same centrifuge as described above to collect the supernatant, which was then centrifuged again under the same conditions to obtain a protein extract from which starch granules had been removed. 3.2 kg of salt was added and dissolved in 160 L of this solution, and 6N hydrochloric acid was further added to adjust the pH to 10.0. Centrifuge under the same conditions as above to collect the precipitate (residual fraction), and the supernatant is further transferred to a Kokusan cooling high-speed centrifuge H-2000B equipped with a continuous rotor QNS at a flow rate of about 2 L / min. The precipitate was removed by continuous centrifugation at a rotation speed of 15,000 rpm. The pH of the centrifugation supernatant was adjusted to 3.0, and the precipitated precipitate was recovered by the same continuous centrifugation. The precipitate was suspended in 5 L of distilled water, stirred at room temperature for 1 hour, and then the precipitate was recovered by centrifugation again and freeze-dried to obtain a globulin fraction.
The residue fraction was suspended again in 100 L of water and then centrifuged under the same conditions to recover the precipitate, which was then freeze-dried to obtain a glutelin + prolamin fraction.
[米ペプチドの調製]
米胚乳タンパク質、アルブミン画分、グロブリン画分、グルテリン+プロラミン画分それぞれ2gを100mlLの蒸留水に懸濁し、リン酸を加えてpH1.85に調整した。これにペプシン(ブタ胃由来、シグマ社製)10mgを添加して37℃で30分間反応させた。反応液に水酸化カルシウムを加えてpH7.0に中和した。沸騰水中で10分間処理して酵素を失活させ、遠心分離により上清を回収した。回収した上清を一夜冷凍後に解凍し、再度遠心分離を行って沈殿を除去し、これを凍結乾燥してペプチドを回収した。
本明細書では米胚乳タンパク質、アルブミン画分、グロブリン画分、グルテリン+プロラミン画分から得られたペプチドをそれぞれREPH、AlbuminH(AlbH)、GlobulinH(GlbH)、Glutelin+ProlaminH(GluProH)と称する。
[Preparation of rice peptide]
2 g each of rice endosperm protein, albumin fraction, globulin fraction, and glutelin + prolamin fraction were suspended in 100 mlL of distilled water, and phosphoric acid was added to adjust the pH to 1.85. To this was added 10 mg of pepsin (derived from pig stomach, manufactured by Sigma) and reacted at 37 ° C. for 30 minutes. Calcium hydroxide was added to the reaction solution to neutralize the pH to 7.0. The enzyme was inactivated by treatment in boiling water for 10 minutes, and the supernatant was recovered by centrifugation. The collected supernatant was frozen overnight, thawed, centrifuged again to remove the precipitate, and lyophilized to recover the peptide.
In the present specification, peptides obtained from the rice endosperm protein, albumin fraction, globulin fraction, and glutelin + prolamin fraction are referred to as REPH, AlbuminH (AlbH), GlobulinH (GlbH), and Glutelin + ProlaminH (GluProH), respectively.
[細胞試験]
マウス大腸由来GLUTag細胞(トロント大学のDrucker博士提供)を48ウェルプレートに、サブコンフルエントになるまで2日間培養し、Hepesバッファー(140mM NaCl、4.5mM KCl、20mM Hepes、 1.2mM CaCl2、1.2mM MgCl2、10mM D−グルコース、0.1% BSA、pH7.4)を用いてウェルを洗浄した。
[Cell test]
Mouse colon-derived GLUTag cells (provided by Dr. Drucker, University of Toronto) were cultured in 48-well plates for 2 days until subconfluent, and Hepes buffers (140 mM NaCl, 4.5 mM KCl, 20 mM Hepes, 1.2 mM CaCl 2 , 1, Wells were washed with .2 mM MgCl 2 , 10 mM D-glucose, 0.1% BSA, pH 7.4).
試料(REPH、AlbuminH、GlobulinH、Glutelin+ProlaminH)を濃度5mg/mLで同バッファーに溶解した溶液をそれぞれ80μL添加して37℃にて60分間インキュベーションした。
陰性対照としてペプチドを含有しないバッファーを同様に添加してインキュベートした(図1中、試料Blk)。
上清を回収後、遠心分離(800×g、4℃で5分間)し、その上清60μLを回収し、上清中のGLP−1濃度を市販のELISAキット(EZGLP1T−36K、ミリポア社製)にて測定した。
図1は各試料についてGLUTag細胞によるGLP−1分泌量を比較した結果を示す図である。
図1に示した結果から明らかなように、全ての試料で陰性対照の試料Blkと比較して有意に高いGLP−1の分泌が認められたが、5mg/mLの添加量で比較した場合にはGlobulinHが他と比較して特に高いGLP−1を分泌したことが分かる。
80 μL of each solution of the sample (REPH, AlbaminH, GlobulinH, Glutellin + ProlaminH) dissolved in the same buffer at a concentration of 5 mg / mL was added, and the mixture was incubated at 37 ° C. for 60 minutes.
Peptide-free buffer was similarly added and incubated as a negative control (Sample Blk in FIG. 1).
After collecting the supernatant, centrifuge (800 × g, 4 ° C for 5 minutes), collect 60 μL of the supernatant, and set the GLP-1 concentration in the supernatant to a commercially available ELISA kit (EZGLP1T-36K, manufactured by Millipore). ).
FIG. 1 is a diagram showing the results of comparing the amount of GLP-1 secreted by GLUTag cells for each sample.
As is clear from the results shown in FIG. 1, significantly higher GLP-1 secretion was observed in all the samples as compared with the negative control sample Blk, but when compared with the addition amount of 5 mg / mL. It can be seen that Globulin H secreted a particularly high GLP-1 compared to others.
[門脈血中のGLP−1測定]
9週齢のSD系雄ラットを1週間馴化して10週齢で試験に供した。動物は試験前日より一夜絶食させ、米タンパク質及びその各画分のペプシン消化物0.5gを10mLの蒸留水に溶解した溶液をラット体重kg当り10mL強制経口投与した。15分後に麻酔下で開腹し、門脈血を採取してGLP−1濃度を測定した。各群の動物数6〜7匹における試験結果を統計解析した結果を図2に示した。
図2に示した結果から明らかなように、GlobulinH投与群でのみ有意に高い濃度のGLP−1が認められた。
[Measurement of GLP-1 in portal blood]
9-week-old male SD rats were acclimatized for 1 week and subjected to the test at 10-week-old. The animals were fasted overnight from the day before the test, and a solution of 0.5 g of rice protein and 0.5 g of pepsin digested product thereof in 10 mL of distilled water was orally administered at 10 mL per kg of rat body weight. After 15 minutes, the abdomen was opened under anesthesia, portal vein blood was collected, and the GLP-1 concentration was measured. The results of statistical analysis of the test results for 6 to 7 animals in each group are shown in FIG.
As is clear from the results shown in FIG. 2, a significantly higher concentration of GLP-1 was observed only in the Globulin H-administered group.
[腹腔内糖負荷試験(IPGTT)]
7週齢のSD系雄ラットを1週間馴化して8週齢で試験に供した。動物は前日より一夜絶食させ、米タンパク質及びその各画分のペプシン消化物0.5gを10mLの蒸留水に溶解した溶液をラット体重kg当り10mL強制経口投与した(各群の動物数は6〜9匹)。直後にグルコースを1g/kg体重の用量で腹腔内に投与した。15、30、60、90、120分後に尾静脈より採血し、グルコース濃度を測定した。
図3に示した結果から明らかなように、全ての試料投与群で投与30分及び60分後に対照群と比べて有意に低い血糖値を示し、GlobulinH投与群では投与15分後でも有意に低い血糖値を示したことから、GlobulinHによる迅速な血糖値への効果にGLP−1分泌活性が寄与していると考えられた。
[Intraperitoneal glucose tolerance test (IPGTT)]
7-week-old male SD rats were acclimatized for 1 week and subjected to the test at 8 weeks of age. The animals were fasted overnight from the previous day, and 10 mL of a solution of rice protein and 0.5 g of pepsin digested product of each fraction in 10 mL of distilled water was orally administered by gavage (the number of animals in each group was 6 to 6). 9 animals). Immediately after, glucose was intraperitoneally administered at a dose of 1 g / kg body weight. After 15, 30, 60, 90 and 120 minutes, blood was collected from the tail vein and the glucose concentration was measured.
As is clear from the results shown in FIG. 3, blood glucose levels were significantly lower in all
Claims (12)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016095639A JP6977945B2 (en) | 2016-05-11 | 2016-05-11 | A composition for promoting GLP-1 secretion and a method for producing the composition. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016095639A JP6977945B2 (en) | 2016-05-11 | 2016-05-11 | A composition for promoting GLP-1 secretion and a method for producing the composition. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017203002A JP2017203002A (en) | 2017-11-16 |
| JP6977945B2 true JP6977945B2 (en) | 2021-12-08 |
Family
ID=60323014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016095639A Active JP6977945B2 (en) | 2016-05-11 | 2016-05-11 | A composition for promoting GLP-1 secretion and a method for producing the composition. |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP6977945B2 (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5189365B2 (en) * | 2005-09-05 | 2013-04-24 | 築野食品工業株式会社 | Body lipid improving composition |
| JP2011068588A (en) * | 2009-08-25 | 2011-04-07 | Oriza Yuka Kk | Body weight increase inhibitor |
| JP5887630B2 (en) * | 2011-08-11 | 2016-03-16 | 岡山県 | Method for producing dipeptidyl peptidase-IV inhibitor |
| JP6139150B2 (en) * | 2013-01-31 | 2017-05-31 | 国立大学法人 新潟大学 | Protein nutritional composition |
| JP2014233266A (en) * | 2013-06-04 | 2014-12-15 | 国立大学法人 新潟大学 | Rice bran protein-containing nutritive composition for inhibiting development of diabetic nephropathy |
| JP2016172693A (en) * | 2013-12-24 | 2016-09-29 | 亀田製菓株式会社 | Serum uric acid lowering agent containing rice protein as active ingredient |
-
2016
- 2016-05-11 JP JP2016095639A patent/JP6977945B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017203002A (en) | 2017-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101426513A (en) | Composition containing peptide as active ingredient | |
| WO2017076112A1 (en) | Oyster peptide capable of enhancing sexual function, and preparation method and application thereof | |
| US8257758B2 (en) | Process for the extraction, purification and enzymatic modification of soy 7S globulin alpha' subunit for use as hypocholesterolemizing agent | |
| TW201642881A (en) | Water-soluble mussel extract | |
| EP3142681B1 (en) | Peptides and compositions thereof for improvement of glycaemic management in a mammal | |
| Chen et al. | Anti-hyperuricemia bioactive peptides: a review on obtaining, activity, and mechanism of action | |
| JP2012244930A (en) | Method for producing collagen peptide from bonito bone as raw material | |
| JPH05112455A (en) | Colon cancer suppressing substance | |
| JP2004097021A (en) | Wakame protein-containing composition and food | |
| JP6977945B2 (en) | A composition for promoting GLP-1 secretion and a method for producing the composition. | |
| JP2010138143A (en) | Glp-1 secretagogue | |
| CN106173853B (en) | Nutritional composition for reducing blood fat and application thereof | |
| JP3999825B2 (en) | Visceral fat accumulation inhibitor | |
| CN101945665A (en) | A composition containing arazyme for preventing and treating arthritis | |
| CN110484584A (en) | It is a kind of with the preparation method and applications for delaying bone-loss active peptides | |
| CN102573880B (en) | Fat Accumulation Inhibitor | |
| JP5721232B2 (en) | Glucagon-like peptide-1 secretion promoter | |
| JP6139150B2 (en) | Protein nutritional composition | |
| JP6083085B2 (en) | Angiotensin converting enzyme inhibitor and use thereof | |
| JPWO2006132273A1 (en) | Composition containing peptide having antifeedant action | |
| JP4929455B2 (en) | Composition comprising pork-derived peptide having antifeedant action | |
| JP2019030229A (en) | Aspergillus oryzae, enzyme derived from aspergillus oryzae, blood glucose level rise inhibitor, food and beverage, pharmaceutical composition, food additive, supplement and manufacturing methods for the same, blood glucose level rise inhibiting method, and sugar uptake promotion method | |
| EP0618229A1 (en) | Amylase inhibitors | |
| WO1995026984A1 (en) | Process for producing composition containing bovine insulin-like growth factor 1 | |
| WO2011068149A1 (en) | Cholecystokinin secretion enhancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190508 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200317 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200515 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200713 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201027 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201225 |
|
| RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20210325 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20210325 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210325 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210601 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210730 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211005 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211029 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6977945 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |